%0 Journal Article
%T Avances en la inmunosupresi¨®n para el trasplante renal: Nuevas estrategias para preservar la funci¨®n renal y reducir el riesgo cardiovascular
%A Bestard
%A Oriol
%A Campistol
%A Josep M.
%A Morales
%A Jos¨¦ M.
%A S¨¢nchez-Fructuoso
%A Ana
%A Cabello
%A Mercedes
%A Cabello
%A Virginia
%A Pallard¨®
%A Luis M.
%A Griny¨®
%A Josep M.
%J Nefrolog¨ªa (Madrid)
%D 2012
%I Scientific Electronic Library Online
%X the development of new immunosuppressants for renal transplantation is aimed not only at improving short-term outcomes, but also at achieving better safety, cardiovascular, and metabolic profiles and at decreasing nephrotoxicity. belatacept is a fusion protein that inhibits t cell activation by binding to cd80 and cd86 antigens. clinical trials, particularly the benefit and benefit-ext studies, have shown that belatacept preserves function and structure in renal grafts. the effects of belatacept provide long-term, sustained results, and the safety and efficacy of this drug have been demonstrated in cases of renal transplantation from expanded criteria donors. compared to calcineurin inhibitors, belatacept is associated with a lower incidence of chronic allograft nephropathy and a more favourable cardiovascular and metabolic profile.
%K belatacept
%K renal function
%K kidney transplantation.
%U http://scielo.isciii.es/scielo.php?script=sci_abstract&pid=S0211-69952012000500015&lng=en&nrm=iso&tlng=en